StreetInsider.com News Articles

Form S-3 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26998769.html

Form S-3 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26998769.html

Form S-8 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260828/26998754.html

Form S-8 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260828/26998754.html

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 19

Tue, 25 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260825/26975214.html

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 19

Tue, 25 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260825/26975214.html

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400

GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company.

The option award has an exercise price of $5.76 per share, the closing price of the Company’s common stock on August 19, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400

Form ARS ADIAL PHARMACEUTICALS, For: Dec 31

Mon, 24 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260824/26968138.html

Form ARS ADIAL PHARMACEUTICALS, For: Dec 31

Mon, 24 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260824/26968138.html

Form DEF 14A ADIAL PHARMACEUTICALS, For: Sep 17

Mon, 24 Aug 2026 16:06:00 -0400

http://archive.fast-edgar.com/20260824/AV2ZQ22CLZ22V23222ZB22Y2WSFIZ222YQ8Q

Filed on: August 24, 2026

Form DEF 14A ADIAL PHARMACEUTICALS, For: Sep 17

Mon, 24 Aug 2026 16:06:00 -0400

http://archive.fast-edgar.com/20260824/AV2ZQ22CLZ22V23222ZB22Y2WSFIZ222YQ8Q

Filed on: August 24, 2026

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 18

Fri, 21 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260821/26962484.html

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 18

Fri, 21 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260821/26962484.html

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 17

Mon, 17 Aug 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260817/26934773.html

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 17

Mon, 17 Aug 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260817/26934773.html

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Mon, 17 Aug 2026 07:00:00 -0400

Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline

Closed initial $32 million tranche, including the conversion of notes, of an up to $64 million private placement from biotech specialist investors

GLEN ALLEN, Va., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”) today provided a business update and reported its financial results for the 2026 second quarter ended June 30, 2026.